|
Age (years)
|
43.8 ± 16.7
|
41.2 ± 15.3
|
>0.05
|
|
Male
|
51 (63.8 %)
|
280 (60.7 %)
|
>0.05
|
|
Antecedent infections
|
55 (68.75 %)
|
301 (65.3 %)
|
>0.05
|
|
Cranial nerve involvement
|
53 (66.25 %)
|
184 (39.91 %)
|
<0.05
|
|
Facial nerve
|
43 (81.1 %)
|
126 (68.5 %)
|
<0.05
|
|
Glossopharyngeal and vagus nerves
|
30 (56.6 %)
|
50 (27.2 %)
|
<0.05
|
|
Oculomotor and/or abducent nerve
|
12 (15 %)
|
57 (12.4 %)
|
>0.05
|
|
Sensory disturbance
|
36 (45 %)
|
249 (54.0 %)
|
>0.05
|
|
Autonomic dysfunction
|
7 (8.8 %)
|
20 (4.3 %)
|
>0.05
|
|
Pain
|
7 (8.8 %)
|
45 (9.8 %)
|
>0.05
|
|
Hyporeflexia or areflexia
|
79 (98.8 %)
|
434 (94.1 %)
|
>0.05
|
|
Hospital stay (days)
|
38.7 ± 28.3
|
14.6 ± 6.3
|
<0.05
|
|
Treatment modality
| | |
>0.05
|
|
IVIg
|
39 (48.8 %)
|
216 (46.9 %)
| |
|
IVIg + intravenous corticosteroids
|
29 (36.2 %)
|
72 (15.6 %)
| |
|
Intravenous corticosteroids
|
6 (7.5 %)
|
90 (19.5 %)
| |
|
Supportive treatment
|
6 (7.5 %)
|
83 (18.0 %)
| |
